The DOI matches its Crossref record; 115 of the 116 references it cites were found in a registry or an index; 67 of the 92 sources its claims cite were checked for support.
Diagnosis and Treatment of Type 2 Diabetes in Adults
Open accessAbstract
Importance: Type 2 diabetes involves progressive loss of insulin secretion from pancreatic β cells in the setting of insulin resistance and manifests clinically as hyperglycemia. Type 2 diabetes accounts for 90% to 95% of all cases of diabetes globally, with estimates ranging from 589 million to 828 million people worldwide. In the US, type 2 diabetes affects approximately 1 in 6 adults. Observations: Risk factors for type 2 diabetes include older age, family history, overweight or obesity, physical inactivity, gestational diabetes, Hispanic ethnicity, and American Indian or Alaska Native, Asian, or Black race. Diabetes is diagnosed if fasting plasma glucose is greater than or equal to 126 mg/dL, hemoglobin A 1C is greater than or equal to 6.5%, or 2-hour glucose during 75-g oral glucose tolerance testing is greater than or equal to 200 mg/dL. Approximately one-third of adults with type 2 diabetes have cardiovascular disease and 10.1% have severe vision difficulty or blindness. The prevalence of type 2 diabetes is 39.2% among patients with kidney failure. Although weight management is an important component of treatment for type 2 diabetes, no specific diet has been proven to be most effective for improving health outcomes. Physical activity can reduce hemoglobin A 1C by 0.4% to 1.0% and improve cardiovascular risk factors (ie, hypertension and dyslipidemia). Randomized clinical trials have reported absolute reductions in microvascular disease (3.5%), such as retinopathy and nephropathy, myocardial infarction (3.3%-6.2%), and mortality (2.7%-4.9%), with intensive glucose-lowering strategies (hemoglobin A 1C <7%) vs conventional treatment 2 decades after trial completion. First-line medications for type 2 diabetes include metformin and, in patients with cardiovascular or kidney comorbidities or at high cardiovascular risk, glucagon-like peptide-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter 2 inhibitors (SGLT2is). Common add-on medications include dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RAs, dipeptidyl peptidase-4 inhibitors, sulfonylureas, and thiazolidinediones. Approximately one-third of patients with type 2 diabetes require treatment with insulin during their lifetime. Several randomized clinical trials have demonstrated benefits of specific SGLT2i and GLP-1RA medications compared with placebo for atherosclerotic cardiovascular disease (12%-26% risk reduction), heart failure (18%-25% risk reduction), and kidney disease (24%-39% risk reduction) over 2 to 5 years. Most trial participants with type 2 diabetes were taking metformin. High-potency GLP-1RA and dual GIP/GLP-1RA medications result in weight loss of greater than 5% in most individuals with type 2 diabetes, and weight loss may exceed 10%. Conclusions: Type 2 diabetes affects up to 14% of the global population and is associated with preventable long-term complications, such as cardiovascular disease, kidney failure, vision loss, and increased mortality. In addition to lifestyle modifications including diet, exercise, and weight management, metformin is generally first-line therapy for attainment of hemoglobin A 1C targets. For individuals with type 2 diabetes and cardiovascular or kidney disease or at high cardiovascular risk, guidelines recommend early treatment with SGLT2i and/or GLP-1RA medications.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This JAMA review summarizes current evidence on diagnosis and treatment of type 2 diabetes in adults, emphasizing individualized glycemic targets, lifestyle and weight management, metformin as general first-line therapy, and early SGLT2i/GLP-1RA use for patients with cardiovascular or kidney disease or high cardiovascular risk. It reports global prevalence estimates up to 14%, diagnostic thresholds, and trial-based reductions in microvascular and macrovascular complications with intensive glucose lowering and newer agents.
Key findings
- Type 2 diabetes accounts for 90% to 95% of diabetes cases globally, with worldwide estimates of 589 million to 828 million people and US adult prevalence of 15.8%; up to 14% of the global population is affected.
- Diagnosis is based on fasting plasma glucose ≥126 mg/dL, HbA1c ≥6.5%, or 2-hour plasma glucose ≥200 mg/dL during 75-g oral glucose tolerance testing, with confirmation by repeat or different test.
- Lifestyle interventions can improve outcomes: physical activity at an optimal dose of 1100 metabolic-equivalent minutes/week (≈244 minutes/week moderate-intensity) reduced HbA1c by 0.4% to 1.0%; the DiRECT trial achieved remission in 46% vs 4% at 12 months; Look AHEAD showed no primary cardiovascular outcome difference over median 9.6 years but sustained weight loss and other benefits.
- For cardiovascular/kidney risk, SGLT2i and GLP-1RA trials showed benefits: SGLT2i meta-analysis of 46,969 participants reduced 3-point MACE (HR, 0.90 [95% CI, 0.85–0.95]); GLP-1RA meta-analysis of 56,004 participants reduced MACE (10.5% vs 11.8%; HR, 0.88 [95% CI, 0.82–0.94]); high-potency GLP-1RAs and dual GIP/GLP-1RAs produced >5% weight loss in most, sometimes >10%.
Methods
- Narrative review: PubMed search for English-language articles published within 5 years before and through June 12, 2024, updated through February 14, 2025, using title keywords for diagnosis and treatment of type 2 diabetes; supplemented by references from selected articles and relevant practice guidelines.
- Of 2016 articles identified, 126 were included: 47 randomized clinical trials, 22 observational studies, 21 systematic reviews and/or meta-analyses, 21 guidelines, 12 narrative reviews, and 3 drug or device reference guides.
- Laboratory values are reported primarily in conventional units, with conversion factors provided for glucose and HbA1c.
Limitations
- Stated: this is not a systematic review and the quality of included literature was not formally evaluated; relevant articles may have been missed; cardiovascular outcome trials generally did not include individuals at lower cardiovascular risk; trials of newer glucose-lowering drugs such as SGLT2is and GLP-1RAs were of relatively short duration, so long-term effects are unknown.
- Evident: as a narrative review, the synthesis and recommendations may be subject to selection and interpretation bias, and no formal risk-of-bias or certainty-of-evidence assessment is reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
23 Couldn’t confirm · 16 Partly supported · 10 No full text of the sources · 5 Own method · 5 Own interpretation · 4 Not supported · 4 No basis given · 1 Supported · accuracy not yet measured
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The Action for Health in Diabetes (Look AHEAD) randomized clinical trial (including 5145 overweight persons with type 2 diabetes) reported that a long-term behavioral weight loss intervention including a goal of at least 175 minutes per week of moderate-intensity physical activity, compared with diabetes self-management education and support, resulted in no difference between groups for the”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Health Behaviors
What the sources say
- Disputedcites [35] Wing RR; Look AHEAD Research Group. Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? findings from the Look AHEAD randomized trial. Obesity (Silver Spring). 2021; 29(8): 1246– 1258. doi: 10.1002/oby.23158 33988896 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plainn = 5,145- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In a trial of 7447 participants in Spain at high cardiovascular risk (50% with diabetes), the 5-year absolute risk of the cardiovascular primary end point (myocardial infarction, stroke, or death from cardiovascular causes) was 3.8% (95% CI, 3.2%–4.4%) in the group randomized to receive a Mediterranean diet combined with extra virgin olive oil or nuts vs 5.7% (95% CI, 4.6%–6.9%) in the control”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Health Behaviors
What the sources say
- Disputedcites [28] Estruch R, Ros E, Salas-Salvadó J,; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018; 378(25): e34. doi: 10.1056/NEJMoa1800389 29897866 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In individuals with prediabetes, type 2 diabetes can be prevented or delayed with changes in health behaviors that lead to weight loss or pharmacotherapy.8”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Could not verifycites [8] Echouffo-Tcheugui JB, Perreault L, Ji L, Dagogo-Jack S. Diagnosis and management of prediabetes: a review. JAMA. 2023; 329(14): 1206– 1216. doi: 10.1001/jama.2023.4063 37039787 sourceExperimental — accuracy not yet measured
The Methods (page unavailable) define prediabetes, and the Results report its prevalence, but neither addresses whether type 2 diabetes can be prevented or delayed. Searches for weight loss, lifestyle intervention, and pharmacotherapy found no passage supporting the attributed claim. (LLM, conf=0.76)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Approximately one-third of patients with type 2 diabetes require treatment with insulin during their lifetime.”
- Also stated in: § Glucose-Lowering Medications for Type 2 Diabetes · hedged
“Insulin therapy is eventually required by up to one-third of adults with type 2 diabetes to maintain glycemic goals as β-cell function declines.14,103”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > OBSERVATIONS
What the sources say
- Could not verifycites [14] American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. Diabetes Care. 2025; 48(1)(suppl 1): S1– S5. doi: 10.2337/dc25-SINT 39651982 PMC11635031 sourceExperimental — accuracy not yet measured
The Results (Patient characteristics) describe the reviewed patients but give no proportion who required insulin. The Background discusses diabetes management without addressing lifetime insulin use; searches for insulin treatment and a one-third lifetime proportion found no supporting passage in our copy. The approximately 32.2% figure in the Abstract (Conclusions) refers to cardiovascular disease prevalence, not insulin treatment. (LLM, conf=0.73)
- Could not verifycites [103] Centers for Disease Control and Prevention. United States Diabetes Surveillance System (USDSS). Accessed February 25, 2025. https://gis.cdc.gov/grasp/diabetes/diabetesatlas-surveillance.html sourceExperimental — accuracy not yet measured
The Other Glucose-Lowering Medications section discusses insulin therapy but gives no estimate of how many people with type 2 diabetes require it during their lifetime. Searches for “one-third,” “30%,” and lifetime insulin use found no supporting passage in our copy, which is truncated at the end. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Glucose-Lowering Medications for Type 2 Diabetes · hedged
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A randomized trial of 5047 patients with type 2 diabetes who were taking metformin assigned patients to receive a sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide), or basal insulin glargine. At 5 years of follow-up, the incidence of HbA1C greater than 7.0% was lower with the addition of insulin glargine or liraglutide (26.5 and 26.1 per 100”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glucose-Lowering Medications for Type 2 Diabetes
What the sources say
- Partly supportedcites [91] Nathan DM, Lachin JM, Balasubramanyam A,; GRADE Study Research Group. Glycemia reduction in type 2 diabetes: glycemic outcomes. N Engl J Med. 2022; 387(12): 1063– 1074. doi: 10.1056/NEJMoa2200433 36129996 PMC9829320 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirectn = 5,047 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“SGLT2 inhibitors have beneficial effects on kidney outcomes including reduced progression to kidney failure, eGFR decline to less than 10 to 15 mL/min/1.73 m2, decrease in eGFR of at least 40%, or death from kidney causes in trials that included people with type 2 diabetes and CKD.14”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Comorbidity Considerations When Selecting Glucose-Lowering Medications
What the sources say
- Could not verifycites [14] American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. Diabetes Care. 2025; 48(1)(suppl 1): S1– S5. doi: 10.2337/dc25-SINT 39651982 PMC11635031 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple trials have demonstrated that achieving an HbA1C less than 7% in nonpregnant adults reduces the risk of microvascular complications such as retinopathy, neuropathy, and nephropathy.14”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glycemic Targets for Microvascular and Macrovascular Complications
What the sources say
- Partly supportedcites [14] American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. Diabetes Care. 2025; 48(1)(suppl 1): S1– S5. doi: 10.2337/dc25-SINT 39651982 PMC11635031 sourceExperimental — accuracy not yet measured
The Background (page not available) says intensive glycemic control is well established as protection against microvascular complications in people with type 1 diabetes. It does not establish an HbA1c target below 7% for nonpregnant adults or specify reduced risks of retinopathy, neuropathy, and nephropathy; searches for the threshold and those complications found no supporting passage. (LLM, conf=0.86)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The UK Prospective Diabetes Study randomly assigned 4209 patients with newly diagnosed type 2 diabetes to receive conventional (primarily diet) vs intensive (insulin, sulfonylurea, or, if overweight, metformin) treatment, with mean attained HbA1C of 7.9% vs 7.0%, respectively.36,37”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glycemic Targets for Microvascular and Macrovascular Complications
What the sources say
- Partly supportedcites [36] UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131): 837– 853. doi: 10.1016/S0140-6736(98)07019-6 9742976 sourceExperimental — accuracy not yet measured
The References section identifies UKPDS 33 as comparing intensive blood-glucose control with sulfonylureas or insulin against conventional treatment in patients with type 2 diabetes. Our copy does not give the claimed 4209 participants, newly diagnosed status, metformin or diet regimens, or attained HbA1c values of 7.9% and 7.0%. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [37] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352(9131): 854– 865. doi: 10.1016/S0140-6736(98)07037-8 9742977 source
plainn = 4,209- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patients in the GLP-1RA group had more weight loss (mean, −3.5 kg).”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glucose-Lowering Medications for Type 2 Diabetes
What the sources say
- Supportedcites [91] Nathan DM, Lachin JM, Balasubramanyam A,; GRADE Study Research Group. Glycemia reduction in type 2 diabetes: glycemic outcomes. N Engl J Med. 2022; 387(12): 1063– 1074. doi: 10.1056/NEJMoa2200433 36129996 PMC9829320 source
The Results section (‘Serious and Targeted Adverse Events and Effects on Weight’; page not provided) reports that the liraglutide group lost a mean of 3.5 kg over four years, more than each of the other treatment groups. The Discussion repeats the 3.5-kg figure. (LLM, conf=0.93)
plaindirectn = 5,047- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a randomized multicenter clinical trial of 319 patients over 13 weeks, use of an automated insulin pump paired with CGM and an algorithm to automatically adjust insulin delivery based on real-time glucose levels led to a mean HbA1C reduction of −0.6% (95% CI, –0.8% to –0.4%; P < .001) compared with multiple daily injections of insulin and CGM alone.104”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glucose-Lowering Medications for Type 2 Diabetes
What the sources say
- Partly supportedcites [104] Kudva YC, Raghinaru D, Lum JW,; 2IQP Study Group. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med. Published online May 8, 2025. doi: 10.1056/NEJMoa2415948 40105270 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plaindirectn = 319- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
- It may state two separate claims as one. 31
- The quote only partly states this claim. 2
- Probably not a substantial claim. 19
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.66–69,88”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Comorbidity Considerations When Selecting Glucose-Lowering Medications
What the sources say
- Could not verifycites [66] McMurray JJV, Solomon SD, Inzucchi SE,; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995– 2008. doi: 10.1056/NEJMoa1911303 31535829 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Disputedcites [67] Packer M, Anker SD, Butler J,; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15): 1413– 1424. doi: 10.1056/NEJMoa2022190 32865377 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
- Could not verifycites [68] Anker SD, Butler J, Filippatos G,; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021; 385(16): 1451– 1461. doi: 10.1056/NEJMoa2107038 34449189 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Disputedcites [69] Solomon SD, McMurray JJV, Claggett B,; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022; 387(12): 1089– 1098. doi: 10.1056/NEJMoa2206286 36027570 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
- Disputedcites [88] Wiviott SD, Raz I, Bonaca MP,; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019; 380(4): 347– 357. doi: 10.1056/NEJMoa1812389 30415602 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The DiRECT Study, an open-label, cluster-randomized trial of 306 individuals from 49 primary care practices in the UK, reported that a very low–calorie formula diet (825–853 kcal/d) followed by stepped food reintroduction achieved remission of type 2 diabetes (HbA1C <6.5% without diabetes medications for at least 2 months) among 46% of participants in the intervention group vs 4% in the control”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Health Behaviors
What the sources say
- Disputedcites [34] Lean ME, Leslie WS, Barnes AC, Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018; 391(10120): 541– 551. doi: 10.1016/S0140-6736(17)33102-1 29221645 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 1 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
Checked by a reasoning model — may be wrong.
plaindirectn = 306- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The quote only partly states this claim.
- Disputed
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Diabetes-related comorbidities also include metabolic dysfunction–associated steatotic liver disease,19 cancers such as colorectal and breast,20 and dementia.21”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Not checked — no full text of the sourcecites [19] Younossi ZM, Golabi P, Price JK, The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2024; 22(10): 1999– 2010.e8. doi: 10.1016/j.cgh.2024.03.006 38521116 source
- Could not verifycites [20] Casagrande SS, Menke A,, eds. Diabetes in America. 3rd ed. 2018. 33651524 sourceExperimental — accuracy not yet measured
Citation 21 is attached to dementia, so that is the part assessed here. The Background discusses metabolic syndrome and heart-disease risk in people with type 2 diabetes, but neither it nor the retrieved passages address dementia (searched: dementia, cognitive decline, Alzheimer’s disease, cognitive impairment). (LLM, conf=0.76)
- Could not verifycites [21] Pearson-Stuttard J, Buckley J, Cicek M, Gregg EW. The changing nature of mortality and morbidity in patients with diabetes. Endocrinol Metab Clin North Am. 2021; 50(3): 357– 368. doi: 10.1016/j.ecl.2021.05.001 34399950 sourceExperimental — accuracy not yet measured
The Introduction discusses cardiovascular disease in people with diabetes, and the Discussion addresses DASH-related cardiometabolic outcomes. Searches for steatotic liver disease, colorectal and breast cancer, and dementia found no passage identifying them as diabetes-related comorbidities. (LLM, conf=0.72)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, most individuals with type 2 diabetes are asymptomatic at diagnosis, and routine screening is recommended (Box 2).14,22”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Diagnosis
What the sources say
- Could not verifycites [14] American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. Diabetes Care. 2025; 48(1)(suppl 1): S1– S5. doi: 10.2337/dc25-SINT 39651982 PMC11635031 sourceExperimental — accuracy not yet measured
The Discussion section on CVD risk assessment discusses screening people who already have type 2 diabetes for cardiovascular risk; it does not say that most people with type 2 diabetes are asymptomatic at diagnosis or recommend routine screening to diagnose diabetes. Searches for asymptomatic diagnosis and routine diabetes screening found no passage addressing those claims. (LLM, conf=0.76)
- Could not verifycites [22] US Preventive Services Task Force. Screening for prediabetes and type 2 diabetes: US Preventive Services Task Force recommendation statement. JAMA. 2021; 326(8): 736– 743. doi: 10.1001/jama.2021.12531 34427594 sourceExperimental — accuracy not yet measured
Participant Selection and Randomization (p. 2) identifies type 2 diabetes as an eligibility criterion, and End Points (p. 7) defines how diabetes was classified. Neither addresses whether most people are asymptomatic at diagnosis or recommends routine diabetes screening; searches for those points found no supporting passage in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although the global prevalence is rising (estimates range from 11%–14% of adult population), the incidence of type 2 diabetes has stabilized or decreased in most places worldwide.6,7”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Could not verifycites [6] Magliano DJ, Islam RM, Barr ELM, Trends in incidence of total or type 2 diabetes: systematic review. BMJ. 2019; 366: l5003. doi: 10.1136/bmj.l5003 31511236 PMC6737490 sourceExperimental — accuracy not yet measured
The Introduction reports U.S. diabetes prevalence and a projected increase in the United States, not a global adult prevalence of 11%–14%. Searches for worldwide incidence trends and stabilized or declining incidence found no passage addressing those claims. The Results likewise concern U.S. prevalence, not global trends. (LLM, conf=0.76)
- Partly supportedcites [7] Global Burden of Disease Study 2021: results. Institute for Health Metrics Evaluation. Accessed February 23, 2025, https://vizhub.healthdata.org/gbd-results/ sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes type 2 diabetes as having a rising trend over past decades, supporting the general statement that its burden is rising. It does not give an 11%–14% prevalence estimate or say that incidence has stabilized or decreased in most places worldwide; the Results examine adiposity and diabetes risk, not global incidence trends. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The number of people with diabetes worldwide was estimated to be between 589 million and 828 million during 2022 to 2024,1,2”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022. Lancet. 2024; 404(10467): 2077– 2093. doi: 10.1016/S0140-6736(24)02317-1 39549716 PMC7616842 sourceExperimental — accuracy not yet measured
The Results (page not provided) estimate that 828 million adults worldwide had diabetes in 2022. The cited paper does not give a 589 million estimate or an estimate for 2024, so it supports only the 2022 figure, not the stated range across 2022–2024. (LLM, conf=0.88)
- Could not verifycites [2] International Diabetes Federation. IDF Diabetes Atlas, 11th edition. Accessed April 30, 2025. https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025.pdf sourceExperimental — accuracy not yet measured
The Summary reports diabetes prevalence in U.S. adults during August 2021–August 2023, not a worldwide count. Searches for worldwide estimates and the figures 589 million and 828 million found no passage addressing the claimed global estimate. (LLM, conf=0.78)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The prevalence of diabetes in US adults is 15.8%.4”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Could not verifycites [4] Gwira JA, Fryar CD, Gu Q. Prevalence of total, diagnosed, and undiagnosed diabetes in adults: United States, August 2021-August 2023. NCHS Data Brief. 2024; 516(516): CS354814. doi: 10.15620/cdc/165794 PMC12035661 40085919 sourceExperimental — accuracy not yet measured
The Introduction discusses rising diabetes prevalence generally, while the Results report incidence trends, including US studies. Searches for “15.8” and US adult diabetes prevalence found no passage giving the claimed 15.8% estimate; our copy therefore does not verify it. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Diabetes is a leading cause of kidney failure, nontraumatic lower extremity amputation, and death (30.4 deaths per 100 000 population).3,18”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Not checked — no full text of the sourcecites [3] Centers for Disease Control and Prevention. National Diabetes Statistics Report 2024. Department of Health and Human Services; 2024. Accessed February 23, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html source
- Could not verifycites [18] Diabetes. Centers for Disease Control and Prevention National Center for Health Statistics. Accessed February 23, 2025. https://www.cdc.gov/nchs/fastats/diabetes.htm sourceExperimental — accuracy not yet measured
The Methods (Participants) and Results passages describe diabetes classification and treatment in the DARE cohort, not population-level complications or mortality. Searches for kidney failure, lower-extremity amputation, and 30.4 deaths per 100,000 found no passage in our copy addressing the claim. Page numbers were not available. (LLM, conf=0.75)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“High-potency GLP-1RA and dual GIP/GLP-1RA medications result in weight loss of greater than 5% in most individuals with type 2 diabetes, and weight loss may exceed 10%.”
- Also stated in: § Glucose-Lowering Medications for Type 2 Diabetes · plain
“Newer, high-potency weekly GLP-1RAs (ie, high-dose semaglutide or dulaglutide) and dual GIP/GLP-1RAs (ie, tirzepatide) are associated with mean HbA1C reductions up to approximately 2% to 2.5% and weight reductions of greater than 5% from baseline in most individuals, with some exceeding 10%.80”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > OBSERVATIONS
What the sources say
- Could not verifycites [80] Frías JP, Davies MJ, Rosenstock J,; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021; 385(6): 503– 515. doi: 10.1056/NEJMoa2107519 34170647 sourceExperimental — accuracy not yet measured
The Effect on Cardiovascular Risk Factors section reports a 1.8 kg greater weight reduction with dapagliflozin than with placebo. It notes some GLP-1 receptor agonist use but does not report weight-loss outcomes for high-potency GLP-1RA or dual GIP/GLP-1RA medications. Searches for those medications and the claimed 5% and 10% thresholds found no supporting passage in our copy. (LLM, conf=0.77)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Glucose-Lowering Medications for Type 2 Diabetes · plain
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“HbA1C generally has greater reliability than glucose levels, but may not accurately reflect time-averaged glucose levels in individuals with some hemoglobinopathies, pregnancy, HIV, recent blood transfusion, iron deficiency anemia, hemodialysis, or hemolytic anemia.14,23”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Diagnosis
What the sources say
- Could not verifycites [14] American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. Diabetes Care. 2025; 48(1)(suppl 1): S1– S5. doi: 10.2337/dc25-SINT 39651982 PMC11635031 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [23] Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. World Health Organization; 1999. Accessed February 23, 2025. https://iris.who.int/bitstream/handle/10665/70523/WHO_NMH_CHP_CPM_11.1_eng.pdf 26158184 source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Type 2 diabetes accounts for 90% to 95% of all cases of diabetes globally”
- Also stated in: § CONCLUSIONS · plain
“with type 2 diabetes comprising 90% to 95% of cases.1,3,4”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > IMPORTANCE
What the sources say
- Partly supportedcites [1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022. Lancet. 2024; 404(10467): 2077– 2093. doi: 10.1016/S0140-6736(24)02317-1 39549716 PMC7616842 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that most diabetes cases in adults are type 2, but gives a range of 85–95%, not 90–95%. It does not extend that proportion to all diabetes cases across all ages globally. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Centers for Disease Control and Prevention. National Diabetes Statistics Report 2024. Department of Health and Human Services; 2024. Accessed February 23, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html source
- Partly supportedcites [4] Gwira JA, Fryar CD, Gu Q. Prevalence of total, diagnosed, and undiagnosed diabetes in adults: United States, August 2021-August 2023. NCHS Data Brief. 2024; 516(516): CS354814. doi: 10.15620/cdc/165794 PMC12035661 40085919 sourceExperimental — accuracy not yet measured
The Discussion (Principal findings; page unavailable) says type 2 diabetes incidence in adults is an order of magnitude greater than type 1 incidence. That supports the general point that type 2 predominates, but it does not establish that type 2 accounts for 90%–95% of all diabetes cases globally; the passage concerns adult incidence, not the global share of existing cases. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § CONCLUSIONS · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Risk factors for type 2 diabetes include overweight and obesity, physical inactivity, age, family history, race and ethnicity, history of gestational diabetes, and presence of other conditions (eg, hypertension, dyslipidemia, cardiovascular disease).9–14”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Not checked — no full text of the sourcecites [9] Moonesinghe R, Beckles GLA, Liu T, Khoury MJ. The contribution of family history to the burden of diagnosed diabetes, undiagnosed diabetes, and prediabetes in the United States: analysis of the National Health and Nutrition Examination Survey, 2009–2014. Genet Med. 2018; 20(10): 1159– 1166. doi: 10.1038/gim.2017.238 29369292 PMC6060023 source
- Partly supportedcites [10] Jayedi A, Soltani S, Motlagh SZ, Anthropometric and adiposity indicators and risk of type 2 diabetes. BMJ. 2022; 376: e067516. doi: 10.1136/bmj-2021-067516 35042741 PMC8764578 sourceExperimental — accuracy not yet measured
The Discussion identifies a history of gestational diabetes as a risk factor for later type 2 diabetes, and the Results quantify that increased risk. The paper does not substantiate the sentence’s full list of risk factors, including physical inactivity, overweight or obesity, and the listed other conditions; its race and age analyses did not find significant associations with the study effect size. Page numbers are not available in our copy. (LLM, conf=0.88)
- Partly supportedcites [11] Cheng YJ, Kanaya AM, Araneta MRG, Prevalence of diabetes by race and ethnicity in the United States, 2011–2016. JAMA. 2019; 322(24): 2389– 2398. doi: 10.1001/jama.2019.19365 31860047 PMC6990660 sourceExperimental — accuracy not yet measured
The Discussion reports an association between BMI and diabetes and differences in diabetes prevalence by race and ethnicity. It does not substantiate the rest of the listed risk factors—physical inactivity, age, family history, gestational diabetes, hypertension, dyslipidemia, or cardiovascular disease. Page numbers are not available in our copy. (LLM, conf=0.88)
- Partly supportedcites [12] Aune D, Norat T, Leitzmann M, Tonstad S, Vatten LJ. Physical activity and the risk of type 2 diabetes. Eur J Epidemiol. 2015; 30(7): 529– 542. doi: 10.1007/s10654-015-0056-z 26092138 sourceExperimental — accuracy not yet measured
The Main section identifies environment, lifestyle and heritability as T2D risk factors, and the Mechanistic clusters section links obesity-related processes and metabolic syndrome to T2D risk. The paper does not establish the full attributed list: it does not identify physical inactivity, age, family history or gestational diabetes as risk factors, and its analyses of ancestry groups and cardiovascular outcomes do not establish race or ethnicity or cardiovascular disease as risk factors for developing T2D. Page numbers are not available in our copy. (LLM, conf=0.86)
- Partly supportedcites [13] Juan J, Sun Y, Wei Y, Progression to type 2 diabetes mellitus after gestational diabetes mellitus diagnosed by IADPSG criteria: systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022; 13: 1012244. doi: 10.3389/fendo.2022.1012244 36277725 PMC9582268 sourceExperimental — accuracy not yet measured
The “Genomic Risk Scores for Prediction and Personalization” section describes a type 2 diabetes prediction model using age, parental diabetes, BMI, blood pressure, HDL cholesterol, and triglycerides. The “Genomic Polygenic Prediction” section also links obesity to elevated risk. Our copy does not establish physical inactivity, gestational diabetes, or cardiovascular disease as risk factors, so it does not support the full list. (LLM, conf=0.87)
- Partly supportedcites [14] American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. Diabetes Care. 2025; 48(1)(suppl 1): S1– S5. doi: 10.2337/dc25-SINT 39651982 PMC11635031 sourceExperimental — accuracy not yet measured
The Discussion section, “Obesity as a risk factor for CVD” (page not provided), says that T2DM risk rises with BMI and discusses a difference between Asian and Caucasian populations. It does not establish the rest of the listed factors as risk factors for developing T2DM; much of its discussion instead concerns cardiovascular risk among people who already have T2DM. (LLM, conf=0.86)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In a meta-analysis and systematic review of 15 randomized clinical trials and observational studies (783 255 patients) comparing intensive control (HbA1C <7.5%) vs standard care in adults 60 years or older or frail adults of any age with type 2 diabetes, there was no difference in mortality, but intensive control was associated with both a reduction in microvascular and macrovascular complications”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glycemic Targets for Microvascular and Macrovascular Complications
What the sources say
- Could not verifycites [45] Crabtree T, Ogendo JJ, Vinogradova Y, Gordon J, Idris I. Intensive glycemic control and macrovascular, microvascular, hypoglycemia complications and mortality in older (age ≥60years) or frail adults with type 2 diabetes: a systematic review and meta-analysis from randomized controlled trial and observation studies. Expert Rev Endocrinol Metab. 2022; 17(3): 255– 267. doi: 10.1080/17446651.2022.2079495 35614863 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
plaincorrelationaln = 255- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Studies have been limited by small sample sizes in combination therapy subgroups and trials have not consistently shown benefit for the combination of SGLT2is and GLP-1RAs on cardiovascular and kidney outcomes.73,112”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Treatment Guidelines and Evidence
What the sources say
- Could not verifycites [73] Perkovic V, Tuttle KR, Rossing P,; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024; 391(2): 109– 121. doi: 10.1056/NEJMoa2403347 38785209 sourceExperimental — accuracy not yet measured
The Trial Participants and Limitations sections describe a linagliptin-versus-glimepiride trial, not studies of combined SGLT2 inhibitors and GLP-1 receptor agonists. Searches for that combination, small subgroups, and cardiovascular or kidney outcomes found no passage addressing the claim. Page numbers were unavailable in our copy. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [112] Apperloo EM, Neuen BL, Fletcher RA, Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists. Lancet Diabetes Endocrinol. 2024; 12(8): 545– 557. doi: 10.1016/S2213-8587(24)00155-4 38991584 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, the weight loss intervention was associated with sustained weight loss, lower HbA1C, delayed progression of kidney disease, and improvements in quality of life, depression, sleep apnea, urinary incontinence, and health care utilization and costs.35”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Health Behaviors
What the sources say
- Could not verifycites [35] Wing RR; Look AHEAD Research Group. Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? findings from the Look AHEAD randomized trial. Obesity (Silver Spring). 2021; 29(8): 1246– 1258. doi: 10.1002/oby.23158 33988896 sourceExperimental — accuracy not yet measured
The Results and Discussion describe intensive glucose control in veterans, not the Look AHEAD weight-loss intervention. Although they report lower HbA1c and less progression of albuminuria with intensive glucose control, those findings cannot verify outcomes attributed to Look AHEAD. Searches for Look AHEAD, sustained weight loss, and the listed quality-of-life and cost outcomes found no relevant passage in our copy; page numbers were unavailable. (LLM, conf=0.76)
plaincorrelationaln = 5,145- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In meta-analyses of people with diabetes (type 1 and 2), clinically meaningful HbA1C reductions have been reported for Mediterranean-style vs control diets (difference in HbA1C, −0.39% [95% CI, −0.58% to −0.20%]), the Dietary Approaches to Stop Hypertension vs control diets (difference in HbA1C, −0.53% [95% CI, −0.62% to −0.43%]), and low- vs high-carbohydrate diets (difference in HbA1C at 6 mo, −”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Health Behaviors
What the sources say
- Could not verifycites [25] Sainsbury E, Kizirian NV, Partridge SR, Effect of dietary carbohydrate restriction on glycemic control in adults with diabetes. Diabetes Res Clin Pract. 2018; 139: 239– 252. doi: 10.1016/j.diabres.2018.02.026 29522789 sourceExperimental — accuracy not yet measured
The Conclusions list A1C and healthy eating as outcomes of diabetes self-management education, and the References cite a nutrition-therapy consensus report. Neither passage reports meta-analyses comparing Mediterranean, DASH, or low-carbohydrate diets, or the quoted HbA1C differences. Searches for those diet names and figures found no supporting passage in this paper. (LLM, conf=0.77)
- Not checked — no full text of the sourcecites [26] Zheng X, Zhang W, Wan X, The effects of Mediterranean diet on cardiovascular risk factors, glycemic control and weight loss in patients with type 2 diabetes: a meta-analysis. BMC Nutr. 2024; 10(1): 59. doi: 10.1186/s40795-024-00836-y 38641818 PMC11027355 source
- Could not verifycites [27] Chiavaroli L, Viguiliouk E, Nishi SK, DASH dietary pattern and cardiometabolic outcomes: an umbrella review of systematic reviews and meta-analyses. Nutrients. 2019; 11(2): 338. doi: 10.3390/nu11020338 30764511 PMC6413235 sourceExperimental — accuracy not yet measured
The Discussion reports HbA1c reductions associated with physical activity in people with type 2 diabetes, not dietary comparisons. Searches of our copy for Mediterranean-style, DASH, and low- versus high-carbohydrate diets found no passage reporting the attributed estimates or addressing outcomes in people with type 1 and type 2 diabetes together. Page numbers were not provided for the indexed passages. (LLM, conf=0.76)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In ACCORD, compared with the standard care group, the intensive glycemic control group had increased hypoglycemia (10.5% vs 3.5%; P < .001), weight gain greater than 10% (28% vs 14%; P < .001), and mortality (5% vs 4%; hazard ratio, 1.22 [95% CI, 1.01–1.46]), prompting early trial discontinuation.39,43”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glycemic Targets for Microvascular and Macrovascular Complications
What the sources say
- Partly supportedcites [39] Gerstein HC, Miller ME, Byington RP,; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358(24): 2545– 2559. doi: 10.1056/NEJMoa0802743 18539917 PMC4551392 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Could not verifycites [43] Park L, Wexler D. Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease. Curr Opin Lipidol. 2010; 21(1): 8– 14. doi: 10.1097/MOL.0b013e328332dfaa 19829110 PMC2871337 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Newer, high-potency weekly GLP-1RAs (ie, high-dose semaglutide or dulaglutide) and dual GIP/GLP-1RAs (ie, tirzepatide) are associated with mean HbA1C reductions up to approximately 2% to 2.5% and weight reductions of greater than 5% from baseline in most individuals, with some exceeding 10%.80”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glucose-Lowering Medications for Type 2 Diabetes
What the sources say
- Could not verifycites [80] Frías JP, Davies MJ, Rosenstock J,; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021; 385(6): 503– 515. doi: 10.1056/NEJMoa2107519 34170647 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The 2-hour plasma glucose level is more sensitive for diagnosis than fasting glucose or HbA1C in identifying individuals with diabetes, and is the preferred test to diagnose cystic fibrosis-related diabetes or posttransplant diabetes; however, it is more cumbersome to perform and has greater day-to-day variability.14”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Diagnosis
What the sources say
- Could not verifycites [14] American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. Diabetes Care. 2025; 48(1)(suppl 1): S1– S5. doi: 10.2337/dc25-SINT 39651982 PMC11635031 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Similarly, a meta-analysis of 7 trials of 6 injectable GLP-1RAs and 1 oral GLP-1RA among 56 004 participants with type 2 diabetes (76% with established cardiovascular disease) over a median follow-up of 1.3 to 5.4 years reported a reduction in both the primary major adverse cardiovascular events outcome (10.5% with GLP-1RA treatment vs 11.8% with placebo; hazard ratio, 0.88 [95% CI, 0.82–0.94])”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Comorbidity Considerations When Selecting Glucose-Lowering Medications
What the sources say
- Could not verifycites [108] Kristensen SL, Rørth R, Jhund PS, Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2019; 7(10): 776– 785. doi: 10.1016/S2213-8587(19)30249-9 31422062 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one. The quote only partly states this claim.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Adult-onset type 1 diabetes and other types of diabetes, such as monogenic diabetes syndromes or diabetes secondary to medical conditions such as pancreatitis, may be misdiagnosed as type 2 diabetes, which can potentially delay initiation of appropriate treatment.24”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Diagnosis
What the sources say
- Could not verifycites [24] Thomas NJ, Lynam AL, Hill AV, Type 1 diabetes defined by severe insulin deficiency occurs after 30 years of age and is commonly treated as type 2 diabetes. Diabetologia. 2019; 62(7): 1167– 1172. doi: 10.1007/s00125-019-4863-8 30969375 PMC6559997 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Intensive control reduced retinopathy progression in ACCORD (7.3% vs 10.4%; P = .003)42 and incidence of nephropathy in ADVANCE (4.1% vs 5.2%; P = .006).40”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glycemic Targets for Microvascular and Macrovascular Complications
What the sources say
- Could not verifycites [42] Chew EY, Ambrosius WT, Davis MD,; ACCORD Study Group; ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3): 233– 244. doi: 10.1056/NEJMoa1001288 20587587 PMC4026164 sourceExperimental — accuracy not yet measured
Citation 42 is attached to the ACCORD retinopathy result; the ADVANCE result has a separate citation. Searches of our copy for ACCORD, retinopathy progression, and the reported percentages found no supporting passage. The Methods and Results instead describe a 52-week comparison of insulin detemir and glargine, with glycaemic control and hypoglycaemia outcomes; no page numbers were available. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [40] Patel A, MacMahon S, Chalmers J,; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24): 2560– 2572. doi: 10.1056/NEJMoa0802987 18539916 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In a randomized clinical trial of 224 participants with type 2 diabetes taking insulin, CGM decreased hypoglycemic episodes, reducing time with blood glucose less than 70 mg/dL by 0.47 hours per day compared with BGM.50”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glucose Monitoring
What the sources say
- Could not verifycites [50] Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes. Diabetes Ther. 2017; 8(1): 55– 73. doi: 10.1007/s13300-016-0223-6 28000140 PMC5306122 sourceExperimental — accuracy not yet measured
The Results > Hypoglycaemia section reports hypoglycaemia with tirzepatide versus placebo or basal insulin, not CGM versus BGM. Searches for CGM, 224 participants, and 0.47 hours per day found no passage in our copy addressing the cited trial or its reported result; page numbers were not available. (LLM, conf=0.76)
plaindirectn = 224- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sulfonylureas are inexpensive and have high HbA1C-lowering efficacy.38,81”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Treatment Guidelines and Evidence > Intensification of Therapy
What the sources say
- Not checked — no full text of the sourcecites [38] Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024; 404(10448): 145– 155. doi: 10.1016/S0140-6736(24)00537–3 38772405 source
- Partly supportedcites [81] Rosenstock J, Kahn SE, Johansen OE,; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019; 322(12): 1155– 1166. doi: 10.1001/jama.2019.13772 31536101 PMC6763993 sourceExperimental — accuracy not yet measured
Section 7 (Managing metformin in the elderly; page unavailable) describes sulphonylureas as having efficacy similar to metformin, supporting their glucose-lowering efficacy, but does not characterize their HbA1c-lowering efficacy as high. The Introduction says metformin has a very low cost; it does not say sulphonylureas are inexpensive. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition to weight reduction and decreased glycemia (with diabetes remission in some patients), expected benefits of metabolic surgery include improved quality of life, reduced cardiovascular events, and decreased risk of hepatocellular, colorectal, pancreatic, gallbladder, breast, endometrial, and ovarian cancers.14,123–126”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Treatment Guidelines and Evidence > Metabolic Surgery
What the sources say
- Could not verifycites [14] American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. Diabetes Care. 2025; 48(1)(suppl 1): S1– S5. doi: 10.2337/dc25-SINT 39651982 PMC11635031 sourceExperimental — accuracy not yet measured
The Results and Discussion passages address cardiovascular disease prevalence and the relationship between obesity and cardiovascular risk in people with type 2 diabetes. Searches for metabolic or bariatric surgery and the named cancers found no passage assessing whether surgery improves quality of life or reduces cardiovascular events or cancer risk. No page numbers were supplied for these passages. (LLM, conf=0.75)
- Partly supportedcites [123] Schauer PR, Bhatt DL, Kirwan JP,; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes. N Engl J Med. 2017; 376(7): 641– 651. doi: 10.1056/NEJMoa1600869 28199805 PMC5451258 sourceExperimental — accuracy not yet measured
The Results (Quality of Life) and Discussion report better quality-of-life outcomes after surgery than after medical therapy at five years. The Discussion says the trial was too small and short to detect differences in cardiovascular events; it does not establish a reduction in those events. Our copy does not address risk reductions for the listed cancers. (LLM, conf=0.90)
- Partly supportedcites [124] Courcoulas AP, Patti ME, Hu B, Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. JAMA. 2024; 331(8): 654– 664. doi: 10.1001/jama.2024.0318 38411644 PMC10900968 sourceExperimental — accuracy not yet measured
The “Metabolic Surgery” for Diabetes section supports weight reduction, improved glycemic control, and remission in some patients. The copy lists quality of life and cardiovascular events as outcomes to assess, but does not establish improved quality of life or fewer cardiovascular events; it also does not report reduced risk for the named cancers. No page numbers are available for these passages. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [125] Sjöholm K, Carlsson LMS, Svensson PA, Association of bariatric surgery with cancer incidence in patients with obesity and diabetes. Diabetes Care. 2022; 45(2): 444– 450. doi: 10.2337/dc21-1335 34799430 PMC8914410 source
- Partly supportedcites [126] Wilson RB, Lathigara D, Kaushal D. Systematic review and meta-analysis of the impact of bariatric surgery on future cancer risk. Int J Mol Sci. 2023; 24(7): 6192. doi: 10.3390/ijms24076192 37047163 PMC10094585 sourceExperimental — accuracy not yet measured
The Conclusions (page not provided) report significantly decreased incidence of all seven listed cancers after bariatric surgery. The Introduction mentions improved cardiovascular risk factors, not fewer cardiovascular events; the Discussion mentions impaired quality of life with obesity, not improved quality of life after surgery. Those two benefits are therefore not supported by this source. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“For individuals with type 2 diabetes and cardiovascular or kidney disease or at high cardiovascular risk, guidelines recommend early treatment with SGLT2i and/or GLP-1RA medications.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Conclusions
What the sources say
- Partly supportedcites [14] American Diabetes Association Professional Practice Committee. Standards of care in diabetes: 2025. Diabetes Care. 2025; 48(1)(suppl 1): S1– S5. doi: 10.2337/dc25-SINT 39651982 PMC11635031 sourceExperimental — accuracy not yet measured
The Background (page unavailable) says diabetes guidelines address CVD prevention and that certain antidiabetic treatments lower CVD risk. It does not say guidelines recommend early SGLT2i or GLP-1RA treatment for people with cardiovascular or kidney disease or high cardiovascular risk. The Discussion (page unavailable) instead describes newer drugs as often intended for second- or third-line use. (LLM, conf=0.82)
- Supportedcites [116] Davies MJ, Aroda VR, Collins BS, Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022; 45(11): 2753– 2786. doi: 10.2337/dci22-0034 36148880 PMC10008140 source
The Consensus Recommendations advise use of an SGLT2i or GLP-1 RA with proven benefit for people with established cardiovascular disease or multiple cardiovascular risk factors, and prioritize SGLT2i for heart failure and qualifying chronic kidney disease. They also say the decision should be independent of background metformin use and baseline HbA1c, supporting the claim’s characterization of early treatment. The recommendations distinguish which drug is preferred for particular conditions. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Type 2 diabetes affects up to 14% of the global population and is associated with preventable long-term complications such as cardiovascular disease, kidney failure, vision loss and increased mortality.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Conclusions
What the sources say
- Partly supportedcites [1] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022. Lancet. 2024; 404(10467): 2077– 2093. doi: 10.1016/S0140-6736(24)02317-1 39549716 PMC7616842 sourceExperimental — accuracy not yet measured
The Results (page not provided) report approximately 14% age-standardised diabetes prevalence worldwide in 2022, separately for adult women and men. The Discussion (page not provided) says the surveys generally did not distinguish diabetes types and that 85–95% of adult cases are type 2. The paper therefore does not establish that type 2 diabetes affects 14% of the global population. (LLM, conf=0.90)
- Partly supportedcites [2] International Diabetes Federation. IDF Diabetes Atlas, 11th edition. Accessed April 30, 2025. https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025.pdf sourceExperimental — accuracy not yet measured
The Abstract reports an age-adjusted diabetes prevalence of 14.3% among U.S. adults, which is close to the cited figure. It does not estimate prevalence in the global population or report a separate figure for type 2 diabetes, so it cannot support those qualifiers. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [3] Centers for Disease Control and Prevention. National Diabetes Statistics Report 2024. Department of Health and Human Services; 2024. Accessed February 23, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
In the paper
“Globally, 32.2% of people with type 2 diabetes have cardiovascular disease.17”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Not checked — no full text of the sourcecites [17] Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes. Cardiovasc Diabetol. 2018; 17(1): 83. doi: 10.1186/s12933-018-0728-6 29884191 PMC5994068 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The prevalence of type 2 diabetes is 39.2% among patients with kidney failure.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > OBSERVATIONS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“In the US, 1 in 10 individuals with diabetes have severe vision loss or blindness.3”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Not checked — no full text of the sourcecites [3] Centers for Disease Control and Prevention. National Diabetes Statistics Report 2024. Department of Health and Human Services; 2024. Accessed February 23, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Physical activity can reduce hemoglobin A1C by 0.4% to 1.0% and improve cardiovascular risk factors (ie, hypertension and dyslipidemia).”
- Also stated in: § Health Behaviors · plain
“Dose-associated HbA1C reductions with this level of activity ranged from 0.4% to 1.0%.33”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > OBSERVATIONS
What the sources say
- Not checked — no full text of the sourcecites [33] Gallardo-Gómez D, Salazar-Martínez E, Alfonso-Rosa RM, Optimal dose and type of physical activity to improve glycemic control in people diagnosed with type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2024; 47(2): 295– 303. doi: 10.2337/dc23-0800 38241499 source
plaindirectn = 6,718- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Health Behaviors · plain
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Several randomized clinical trials have demonstrated benefits of specific SGLT2i and GLP-1RA medications compared with placebo for atherosclerotic cardiovascular disease (12%–26% risk reduction), heart failure (18%–25% risk reduction), and kidney disease (24%–39% risk reduction) over 2 to 5 years.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > OBSERVATIONS
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“More than 600 genetic variants are associated with an increased risk of type 2 diabetes.15”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Not checked — no full text of the sourcecites [15] Suzuki K, Hatzikotoulas K, Southam L,; VA Million Veteran Program. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 2024; 627(8003): 347– 357. doi: 10.1038/s41586-024-07019-6 38374256 PMC10937372 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Randomized clinical trials have reported absolute reductions in microvascular disease (3.5%), such as retinopathy and nephropathy, myocardial infarction (3.3%–6.2%), and mortality (2.7%–4.9%), with intensive glucose-lowering strategies (hemoglobin A1C <7%) vs conventional treatment 2 decades after trial completion.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > OBSERVATIONS
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Type 2 diabetes affects up to 14% of the global population and is associated with preventable long-term complications, such as cardiovascular disease, kidney failure, vision loss, and increased mortality.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Although body mass index has a stronger association with type 2 diabetes than genetic risk scores,16 approximately 10% of individuals with type 2 diabetes do not have overweight or obesity.3”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Abstract > CONCLUSIONS
What the sources say
- Not checked — no full text of the sourcecites [16] Meigs JB. The genetic epidemiology of type 2 diabetes: opportunities for health translation. Curr Diab Rep. 2019; 19(8): 62. doi: 10.1007/s11892-019-1173-y 31332628 PMC8059416 source
- Not checked — no full text of the sourcecites [3] Centers for Disease Control and Prevention. National Diabetes Statistics Report 2024. Department of Health and Human Services; 2024. Accessed February 23, 2025. https://www.cdc.gov/diabetes/php/data-research/index.html source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“An observational study that published follow-up data (median of 17.5 years [range, 0–42 years]) on 1489 (97.6%) of the 1525 surviving participants reported reductions in all-cause mortality (2.7%–4.9%), myocardial infarction (3.3%–6.2%), and microvascular disease defined as vitreous hemorrhage, retinal photocoagulation, death due to kidney disease, or kidney failure (3.5%) in those previously”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Management > Glycemic Targets for Microvascular and Macrovascular Complications
What the sources say
- Not checked — no full text of the sourcecites [38] Adler AI, Coleman RL, Leal J, Whiteley WN, Clarke P, Holman RR. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Lancet. 2024; 404(10448): 145– 155. doi: 10.1016/S0140-6736(24)00537–3 38772405 source
plaindirectn = 1,525 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Third, randomized clinical trials investigating cardiovascular outcomes did not generally include individuals at lower risk of cardiovascular disease.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Treatment Guidelines and Evidence > Limitations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fourth, clinical trials of newer glucose-lowering drugs such as SGLT2is and GLP1RAs were of relatively short duration, and long-term effects of these medications are currently unknown.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Treatment Guidelines and Evidence > Limitations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We focused on high-quality studies and supplemented our search by identifying additional articles from references of selected articles and reviewed relevant current practice guidelines.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Methods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“First, it is not a systematic review, and the quality of included literature was not formally evaluated.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Treatment Guidelines and Evidence > Limitations
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Second, relevant articles may have been missed.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Treatment Guidelines and Evidence > Limitations
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We searched PubMed for English-language articles published within 5 years before and through June 12, 2024, and updated the search for additional articles published through February 14, 2025, using title keywords for diagnosis and treatment of type 2 diabetes (Supplement).”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Methods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Of 2016 articles identified, 126 were included, consisting of 47 randomized clinical trials, 22 observational studies, 21 systematic reviews and/or meta-analyses, 21 guidelines, 12 narrative reviews, and 3 drug or device reference guides.”
§ Diagnosis and Treatment of Type 2 Diabetes in Adults > Methods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,379
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Research works printed but not linked: 3
- 1999, Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus
- 2023, Practical Insulin: A Handbook or Prescribing Providers
- International Diabetes Federation. IDF Diabetes Atlas, 11th edition. Accessed April 30, 2025. https://diabetesatlas.org/media/uploads/sites/3/2025/04/IDF_Atlas_11th_Edition_2025.pdf
Cited by
Sorted by citations
12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., Callaghan, B. C., ChallaSivaKanaka, S., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s012 · Cited by 160
Risk Factors for Cardiovascular and Metabolic Disease: Integrating Traditional and Novel Paradigms
Wang, Z., Chen, S., Xu, S., & Weng, J. (2025) · iNew Medicine · doi:10.1002/inm3.70000 · Cited by 24
Zheng, W., Man, Z., Li, Y., & Zhu, X. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03063-2 · Cited by 15
“Despite advances in the management of traditional risk factors such as hypertension [6], dyslipidaemia [7], and diabetes [8], a significant residual risk persists, underscoring the need for better early risk stratification tools.”
The Role of the Gut Microbiome in Type 2 Diabetes Mellitus
Mashal, R., Al-Muhanna, A., Khader, S., Khudair, A. D., Khudair, A. D., & Butler, A. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311412 · Cited by 17
“Encompassing 90–95% of all global diabetes cases, T2DM is characterized by the impaired secretion of insulin from beta cells in the pancreas, along with reduced insulin sensitivity in peripheral tissues, such as skeletal muscle, liver, and adipose tissue [24,25].”
InfluentialZhou, J., Shi, R., Zhang, C., Chen, Y., Ma, X., Hu, Y., He, Y., Tao, G., & Cai, R. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.170173 · Cited by 15
Immune activation induced by dysregulated lipid metabolism in the pathogenesis of type 2 diabetes
Yang, H., Yu, W., Mao, Q., & Zhao, L. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.114395 · Cited by 11
Prepregnancy Care and Counseling
Cooper, K. M., Szymanski, L. M., David, P. S., Allen, S. V., & Breitkopf, D. M. (2026) · JAMA · doi:10.1001/jama.2026.2888 · Cited by 12
MASLD in childhood as a multisystem health challenge beyond the liver
Esposito, M., Rimauro, I., Frattolillo, V., Forcina, G., Marzuillo, P., del Giudice, E. M., & Sessa, A. D. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.10.001 · Cited by 10
Lin, J., Huang, L., Song, L., Shi, J., Chu, X., & Ding, H. (2025) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/14703203251405957 · Cited by 6
Xie, Z., Hu, J., Stallings‐Smith, S., Kulshreshtha, A., & Hong, Y. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251395318 · Cited by 5
“For example, vision loss is impacted by factors such as hypertension 44 – 45 conditions which were both elevated and not suf fi ciently controlled in our study sample of rural adults.”
New Treatment Options for MASLD Patients with Type 2 Diabetes
Mega, A., Turri, C., Marzi, L., Dauriz, M., Sacco, R., Floreani, A., & Stasi, C. (2026) · Life · doi:10.3390/life16020254 · Cited by 8
“It accounts for 90–95% of all diabetes cases globally, with current estimates indicating a worldwide prevalence between 589 and 828 million adults and rising incidence in regions with increasing rates of obesity and sedentary lifestyle [17,23].”
InfluentialCraciun, C. I., Măgureanu, D. C., Bocșan, I. C., Craciun, A. E., Buzoianu, A. D., & Maria Adriana, N. E. A. G. (2026) · Diabetology · doi:10.3390/diabetology7030059 · Cited by 9
Wilmot, E., Moore, P., Sathyapalan, T., Choudhary, P., Lim, J. Z. M., Neupane, S., Crabtree, T. S., Iqbal, A., Evans, M., Rayman, G., et al. (2026) · The Lancet Diabetes and Endocrinology · doi:10.1016/s2213-8587(26)00076-8 · Cited by 5
Šantić, R., Martinovic, L., Pavlović, N., Martinović, D., Vrdoljak, J., Kumrić, M., Vilović, M., & Božić, J. (2026) · Molecules · doi:10.3390/molecules31111840 · Cited by 9
“…metformin for hepatic gluconeogenesis, statins for cholesterol biosynthesis, and SGLT2 inhibitors for renal glucose reabsorption, none of which were designed to address the upstream intestinal permeability defect and endotoxin translocation that initiate and sustain systemic inflammation [107,108].”
Genetics and response to treatment with metformin for type 2 diabetes
Tessier, L., St-Amour, S., Simard, D., Bouchard, J., Perron, P., & Tremblay, K. (2025) · Pharmacogenomics · doi:10.1080/14622416.2025.2565992 · Cited by 4
Diabetes mellitus and risk of multiple sclerosis: a systematic review and meta-analysis
Tang, M., Tang, H., Deng, H., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1724167 · Cited by 4
“As the most prevalent subtype globally, T2DM is de fi ned by core features of insulin resistance coupled with dysfunctional pancreatic b -cells (10).”
Bays, H. E., Varney, C., Alexander, L., Ng, J., Tondt, J., Weber, C., Christensen, S. M., Burridge, K., Brown, C., Bindlish, S., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100283 · Cited by 4
Effectiveness and safety of automated insulin delivery in type 2 diabetes: a meta-analysis
Zeng, B., Jia, H., Yang, S., Zheng, J., Yang, Q., & Dou, L. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02014-x · Cited by 4
Applications of Carbon Dots and Graphene Quantum Dots in Treatment of Diabetes
Nakayama, S., Shepard, E. J., Banerjee, A., Yang, X., & Crans, D. C. (2026) · Molecules · doi:10.3390/molecules31060941 · Cited by 5
“Type 2 diabetes mellitus accounts for about 90–95% of all diabetes cases globally, while Type 1 diabetes mellitus makes up the remaining 5–10% [13].”
GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes by Body Mass Index in Type 2 Diabetes
Ramadurgum, P., Sharma, K. M., Pinon, A., Kattamuri, L. P. V., & Botros, M. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02356-6 · Cited by 3
Etayo-Urtasun, P., de Asteasu, M. L. S., & Izquierdo, M. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103915 · Cited by 3
Repurposed Systemic Pharmacologic Agents in Chronic Pain: Emerging Mechanistic and Clinical Insights
McKenzie, A., Dombrower, R., Bittar, T. G., McKenzie, S. M., Theeraphapphong, N., Shukla, N., Hussain, H., & Abd-Elsayed, A. A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041572 · Cited by 2
Zhang, H., Yue, T., Wang, S., Shi, J., Geng, M., Zhang, H., Pan, L., Gu, Z., Sun, L., ZHAO, M., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156650 · Cited by 2
Yang, Y., Niu, Z., Luo, X., Chen, K., Zhang, X., & Jia, L. (2026) · Foods · doi:10.3390/foods15122086 · Cited by 2
“T2D is the most common type, accounting for approximately 90% of all diabetic patients (Figure 1) [11].”
Li, M., Zhang, Q., Wang, Z., Gui, Z., Liu, J., Li, J., Jiang, M., Chang, Z., Han, Q., Yang, B., et al. (2026) · iMeta · doi:10.1002/imt2.70157 · Cited by 6
Boettger, P., Sedighi, J., Buerke, M., Braun, T., Juenemann, M. B., & Omar, O. A. (2025) · Translational Stroke Research · doi:10.1007/s12975-025-01400-x · Cited by 4
Zhao, L., Zhao, C., Li, A., Gao, Q., Ai, S., Wang, Y., Chen, Z., & Wang, Z. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1671238 · Cited by 2
“%) met the diagnostic criteria for CKD. Compared to participants without CKD, those with CKD were older, had lower educational attainment and household income, and were more likely to be unmarried or living alone.”
InfluentialChen, S., Zeng, M., Shen, X.-X., & Zhang, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26209866 · Cited by 1
“Among the primary types of diabetes, type 2 diabetes mellitus (T2DM) accounts for 90–95%, making it the most common form clinically [4].”
Electronic nose for detecting abnormal glucose metabolism in heart transplant recipients
Wijbenga, N., Muntinga, A. J., Goedendorp-Sluimer, M. M., van Dijk, B. C. J., Roest, S., Brugts, J. J., Çalişkan, K., Constantinescu, A. A., Zandbergen, A. A. M., Bos, D., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02970-8 · Cited by 1
The role of the PPAR system in diabetic cardiovascular risk and beyond
Ruscica, M., Macchi, C., Corsini, A., & Sirtori, C. R. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000943 · Cited by 1
Wu, M., Ma, X., Dai, W., Li, K., Gao, H., Guo, Y., & Xiao, W. (2026) · Biomolecules · doi:10.3390/biom16010115 · Cited by 3
“Type 2 diabetes mellitus (T2DM), a metabolic disease characterized by chronic hyperglycemia, impairs the health and well-being of approximately 14% of the global population [1].”
Riggs, K., Tipton, L., & Joy, S. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.11.001 · Cited by 1
Brennan, E., Das, P., Wasif, P., Wang, X., Mueller, J. F., He, C., Varghese, J. V., Butler, A. E., Atkin, S. L., & Alamuddin, N. (2026) · Journal of Xenobiotics · doi:10.3390/jox16010015 · Cited by 1
“T2D diabetes is a complex metabolic condition with multiple contributing factors, including higher BMI and older age [58].”
Radar-Based Monitoring for Non-Contact Detection of Nocturnal Hypoglycemia in Diabetes: A Review
Ravaioli, C., Mendez, C., Gantner, S., Bader, S. B., & Witthauer, L. (2026) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2026.3663452 · Cited by 1
Consolim‐Colombo, F. M., Précoma, D. B., Camazzola, F. E., ABIB, E., Franco, D. R., Magalhães, L. B. N. C., Spinelli, A. C. D. S., Gemelli, J. R., Borges, J. L. C., Montenegro, R. M., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083022 · Cited by 1
“Recognizing and overcoming therapeutic inertia is essential to improving long-term outcomes in patients with CMM and should be a priority for clinical practice and care quality improvement [12,20–22].”
Lv, N., Sun, H., Chen, X., Dong, H., Tang, W., 蒋轶锋, Hong, L., Li, H., Qiao, Y., Dong, X., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103180 · Cited by 1
Zhang, D., Jia, Z., Geng, A., Zhang, Z., Pan, X., & Zhong, X. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1798444 · Cited by 1
“Recent epidemiological data demonstrate that the global number of individuals afflicted with DR exceeded 103 million in 2021 and is projected to reach 160 million by 2045, thus classifying it as one of the most rapidly expanding causes of visual impairment on a global scale (2).”
Altered mitochondrial functionality in metabolic disorders: insights from Drosophila studies
Zeng, Y., Yang, Y., Zhu, Y., Xu, P., Cheong, C., Zhao, Y. J., & Baeg, G. H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1817121 · Cited by 2
Insulin/IGF signaling in islet biology and its therapeutic implications
Kim, H., & Kulkarni, R. N. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag014 · Cited by 2
Trybulski, R., Żebrowska, A., Fostiak, K., Olaniszyn, G., & Wilk, M. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156671 · Cited by 1
Nikolaidis, C. G., Gyriki, D., Stavropoulou, E., Karlafti, E., Didangelos, T., Tsigalou, C., & Thanopoulou, A. C. (2026) · Microorganisms · doi:10.3390/microorganisms14061285 · Cited by 1
“These complications contribute to increased morbidity and mortality [1,2].”
PROTAC-Mediated DPP-4 Degradation: A New Solution for Type 2 Diabetes
Zeng, W., & Feng, L. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01141 · Cited by 1
Zhou, Z., Wang, Z., Li, G., Zhang, H., Chen, Z., Xia, Y., Wang, Y., & Hu, J. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1787033 · Cited by 1
Liu, H., Zhang, X., Tang, K., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03258-1 · Cited by 1
Tariq, R., Parmar, K., Desai, M., et al. (2026) · United European Gastroenterology Journal · doi:10.1002/ueg2.70255 · Cited by 1
Oral Corticosteroid Bursts and Risk of Serious Adverse Events in Adults With Type 2 Diabetes
Yao, T., Hsu, C.-C., Sheu, W. H., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.35604 · Cited by 1
The need for improved diabetes detection and treatment
Sørensen, H. T. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00250-5
Wen, Y. U., ZHANG, C., Xiao, J., Song, H., XIONG, L., Wang, L., Shen, X., & Wang, F. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2025-0181
Type 2 diabetes in Norway 2009–2021: Have declining incidence rates continued?Preprint
Hindenes, L. B., Ruiz, P. L., Tapia, G., Bakken, I. J., Qvigstad, E., Gulseth, H. L., & Stene, L. C. (2025) · medRxiv · doi:10.1101/2025.09.24.25336539
Kritya, M., Sella, G., Kharsa, C., et al. (2025) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2025.11.007
Basil, B., Mohammed, J. A., Mba, I. N., Okoro, N. I., Myke-Mbata, B. K., & Akujieze, C. J. (2025) · Research Square · doi:10.21203/rs.3.rs-7806539/v1
Three New Aporphine Alkaloids with Glucose Consumption Increase Activity from Cassytha filiformis
Zhang, C., Lin, Y., Xie, L., et al. (2025) · Molecules · doi:10.3390/molecules30234544
“The glucose consumption ability of patients with diabetes is influenced by insulin function, and the decline in this consumption ability is an important aspect of the patho-physiological process of diabetes [17,18].”
Xu, K., Hardin, K., Lenox-Riccelli, D., & Amin, A. N. (2026) · Health Sciences Review · doi:10.1016/j.hsr.2026.100258 · Cited by 1
Lili, N., Liu, T., Lv, Y., Cheng, Y., Yang, M., & Cai, H. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70242
“However, its specific role as an RBP in T2DM is unclear.”
InfluentialVoelker, R. (2026) · JAMA · doi:10.1001/jama.2025.23179
Li, Y., Zhou, G., Yang, F., et al. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12613-2
“T2DM accounts for 90–95% of all diabetes cases worldwide, affecting an estimated 589 to 828 million individuals [5].”
Jia, J., Hao, X., Hu, Y., Haoyang, M. E. N. G., Zhao, C., Guan, J., & Sun, W. (2025) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm66473.2025.11356320
Type 2 diabetes in Norway 2009–2021: Have declining incidence rates continued?
Hindenes, L. B., Ruiz, P. L., Tapia, G., Bakken, I. J., Qvigstad, E., Gulseth, H. L., & Stene, L. C. (2026) · Diabetic Medicine · doi:10.1111/dme.70225
¿Cómo propiciar conductas de adherencia a un plan nutricional?
Bernal-Gómez, S. J., Moreno, A. G. M., & Díaz, M. J. A. (2025) · Ediciones Comunicación Científica eBooks · doi:10.52501/cc.342.03
Jia, H., Liu, S., zhou, M., Cao, Y., Gan, X., He, P., Li, F., Xu, Y., Wang, B., & Xu, X. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-08732-y
Stump, K., Centeno, D., Talsania, A. J., et al. (2026) · Hand · doi:10.1177/15589447261422503
Chin, W.-L., Chen, C.-Y., Tu, W.-L., Chen, J.-H., Yen, Y., & Hung, T.-T. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08530-7
Dai, A., Liu, Y., Yin, J., Wang, Q., Yang, M., Ji, X., & Hu, Z. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1734108
Glucagon-like Peptide-1 Receptor Agonists and Colorectal Cancer Risk
WINKELMAN, J. E., & LeVine, M. J. (2026) · AACE Endocrinology and Diabetes · doi:10.1016/j.aed.2026.02.013
Domain-Specific Knowledge Graphs in RAG-Enhanced Healthcare LLMS
Anuyah, S., Kaushik, M. M., Dai, H., Shiradkar, R., Arjan Durresi, A., & Chakraborty, S. (2025) · IEEE International Conference on Big Data (BigData) · doi:10.1109/bigdata66926.2025.11400857
“What is particularly striking is that over 90% of all diabetes cases are type 2 [8], [9], largely driven by our ageing populations and modern lifestyle factors.”
InfluentialGarg, S., Araujo‐Duran, J., Valencia, S. O., Chatterjee, A., & Lembo, A. J. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251408393
Assessing the impact of the Inflation Reduction Act on Medicare prescription drug coverage
Zhang, Y. W., Blyumin, M. G., Qu, C., et al. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag083
Chen, S., & Lu, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1739521
“…functional reserve may be assessed using fasting and/or stimulated C-P measurements, providing an indication of endogenous insulin secretory capacity and supporting differentiation from alternative low-BMI diabetes presentations when interpreted alongside clinical features as needed (3, 8, 31, 34).”
InfluentialTreatment outcomes in patients with ischemic stroke depending on glycemic status
Yasnii, O. M. (2026) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.22.2.2026.1692
Ma, J.-Q., Sun, Y., Wu, T.-Y., et al. (2026) · Molecules · doi:10.3390/molecules31071137
Chau, L. B., Tri, D. V., Quy, V. T., Tiwari, R., Phan, Q., Kieu, T. T. M., Tho, D. V., Khoi, L. M., Quỳnh, N. T. N., Abdullah, R. M., et al. (2026) · Tropical Medicine and Health · doi:10.1186/s41182-026-00943-5
Niu, C., Yin, J., Li, M., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1817017
“Type 2 diabetes mellitus (T2DM) is the most common form of diabetes, accounting for over 90% of global cases (3).”
Chou, C., Chen, H.-F., Lin, J., Chen, C., Liao, Y., & Yeh, A.-Y. (2026) · Geriatric Nursing · doi:10.1016/j.gerinurse.2026.104043
Martín-Olmedo, J. J., Clavero‐Jimeno, A., Camacho-Cardeñosa, A., Boira-Nacher, B., Merino, J., Piernas, C., Labayen, I., Ruiz, J. R., & Jurado‐Fasoli, L. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106671
Papakitsou, I., Papazachariou, A., & Filippatos, T. D. (2026) · World Journal of Clinical Cases · doi:10.12998/wjcc.v14.i14.120574
Bacterial Extracellular Vesicles in Aging: Mechanisms and Therapeutic Prospects
Tan, J., Zubair, M., Zhang, L. Y., Liu, L.-P., Li, K., Wang, Y., Yan, Y., & Xu, W. (2026) · International Journal of Nanomedicine · doi:10.2147/ijn.s597419
Susanti, E., Kosasih, C., Priambodo, A. P., Juniarti, N., Aziz, M. A., & Afriana, R. (2026) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s605488
shi, G., Abuduaini, S., Chen, L., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1807373
“Managing diabetes and its associated complications, including cardiovascular disease, renal failure, and retinopathy, continues to present a substantial and ongoing challenge (Kalyani et al., 2025).”
Zhu, L., Hongning, L. I., Zhang, Y., Tao, S., Rengna, Y., Luo, Y., Shen, Z., Li, H., Kong, X., & Ma, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1810786
Thirumalai, A., & Hirsch, I. B. (2026) · Diabetes Care · doi:10.2337/dci26-0040
Anthropomorphic Cues in AI Chatbots: Boundary Conditions for Trust Formation
Kummer, T., Bick, M., & Laule, L. (2026) · Lecture notes in business information processing · doi:10.1007/978-3-032-26363-6_8
Toffoli, B., Michieletto, M., Bernardi, S., & Candido, R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114694
“Type 2 diabetes mellitus (T2DM) remains a global health challenge, requiring therapeutic strategies that not only achieve glycemic control but also promote weight loss and reduce diabetic complications [1].”
Fąfara, M., Jeczkało, M., Kosiorowska, M., Kowalczyk, A., Lasoń, J., Makulska, M., Płachta, W., Sęk, W., Sieradzka, A., & Wegenko, C. M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5796
Evaluation of macular microcirculation in prediabetic patients using OCT angiography
Cay, Y., Güney, S. C., Degirmenci, C., Şimşir, İ. Y., Afrashı, F., & SAYGILI, L. F. (2026) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2026.105533
Zhang, C., Huang, Y. X., Fu, G., Zhang, X., & Xia, D. (2026) · Nutrients · doi:10.3390/nu18111776
“It should be noted that food-addictive behaviours lead to excessive calorie intake, and this caloric surplus is itself closely associated with T2DM [129,130].”
Letter to the Editor: Leptin hypomethylation - an early epigenetic marker of lean-type diabetes
Zhao, Z.-Y., Wu, P., & Sun, N. (2026) · World Journal of Diabetes · doi:10.4239/wjd.117113
Renal Biomarkers as Predictors of Renal Damage in Patients With Type 2 Diabetes
Ali, M. O., Billal, D. H., Modawe, G. A., Tamomh, A. G., & Mohamed, A. I. E. (2026) · BioMed Research International · doi:10.1155/bmri/4352812
The hypoglycemic metabolites and potential mechanisms of Lilium lancifolium (Juandan lily)
Wu, Q., Xiao, K., Zhao, D., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1806579
“Long-term T2DM can lead to severe complications affecting the cardiovascular and cerebrovascular systems, kidneys, retina, and nerves (Kalyani, et al., 2025; Grover, et al., 2025).”
Jamal, Y. A., Layon, A. G., Michelin, L., Mateo, D., Panesa, D., Meceda, P., Bevington, S., Hodghead, K., Bennett, J., Powers, L., et al. (2026) · Transfusion · doi:10.1111/trf.70238
Irby, J., Lehnardt, E., Rasizer, L. N., Payton, M. E., & Ryznar, R. J. (2026) · JMIR Formative Research · doi:10.2196/preprints.103864
Spencer, R., Jones, G., McHugh, S., Ajjan, R., Birch, R. J., & Ashley, L. (2026) · British Journal of Health Psychology · doi:10.1111/bjhp.70088
“Suboptimal glycaemic control can cause unpleasant symptoms (e.g. fatigue; inability to concentrate; increased thirst) (Kalyani et al., 2025; Nakhleh & Shehadeh, 2021) which may reduce health-related quality of life (Cannon et al., 2018).”
Zou, H.-Y., Jiang, H., Xiao-di, G., Wen, Z.-Y., Shi, Y., Zhou, A.-D., Wang, M., Xu, F., & Cai, M. (2026) · World Journal of Diabetes · doi:10.4239/wjd.120343
Alajab, J., Vedagarbha, N., Sooch, M. K., Hussein, M., Ahmed, A., & Marzoug, M. (2026) · Cureus · doi:10.7759/cureus.110957
Wei, Y., Mai, Z., Pan, M., Chen, X., Zheng, J., Lin, Y., Li, X., Meng, X., Lin, X., & Zhang, J. I.-X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1851380
Hamdy, N. Μ., El‐Daly, S. M., Elazazy, O. E., Kabel, A. M., Salama, R. M., Gouhar, S. A., Sallam, A.-A. M., & Darwish, S. F. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00801
Gavoyannis, G., Turner, J., Fox, S., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70409
Deng, Q., Wang, Y., Zheng, F., et al. (2026) · eFood · doi:10.1002/efd2.70188
Chen, Y., Zhang, Z. K., Liu, Z., Lv, T., Ye, M., Yan, J., & Zhang, M. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1858507
“…development of novel therapeutic agents for PD. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), established for type 2 diabetes management (6), exhibit diverse therapeutic advantages, including glucose-dependent insulin secretion, preservation of glucose homeostasis, and reduction of…”
Ostrowska, K., Lemieszek, B., Lankauf, K., Szpunar, I., Maximenko, A., Dec, B., Jasiński, P., & Molin, S. (2026) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.6c03237
HbA1c trajectories after SGLT2 inhibitor initiation and the risk of dementia
Zhang, J., Wang, Y., Lu, Z., Yang, Y., Wang, J., Zhao, L., Li, F., Miao, M., Chen, W., Wu, S., et al. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261462927
Metadata
- Authors
- Kalyani, R. R., Neumiller, J. J., Maruthur, N. M., & Wexler, D. J.
- Affiliations
- Johns Hopkins University (US)
- Washington State University Spokane (US)
- Harvard University (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2025-09-16
- Volume
- 334
- Issue
- 11
- Pages
- 984
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC13014273
- OpenAlex
- W4411540721
- Cited by
- 145
- References
- 116
- Citations by year
- 2026: 121 · 2025: 24
- FWCI
- 85.66
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- American Diabetes Association
- Novo Nordisk
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK135043)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, insulin resistance, beta-cell dysfunction, hyperglycemia, diabetes diagnosis, diabetes risk factors, cardiovascular risk, tight glycemic control, metformin, SGLT2 inhibitors, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, insulin therapy
- MeSH terms
- Global Burden of Disease, Adult, Age Factors, Blood Glucose, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin Resistance, Life Style, Medical History Taking, Obesity, Risk Factors, Exercise, Prevalence, Overweight, Sedentary Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
